ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
In silico design, synthesis of a novel chalcone derivative and its in vitro and in vivo anticancer activity against colon cancer-induced mouse model.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to synthesize and evaluate the anticancer activity of novel chalcone derivative against colon cancer by in vitro cytotoxicity against HCT-116 (Research Resource Identifiers:CVCL_D4JB) cell line and in vivo using EAC (Research Resource Identifiers: CVCL_1306) and DLA (Research Resource Identifiers: CVCL_VR37) cells inoculated Swiss albino mice. The present study aimed to synthesize the new chalcone derivatives and conduct its anti-colon cancer activity both in vitro and in vivo. The designed compounds were subjected to in silico studies like binding pocket analysis, molecular docking, and ADME studies. The compounds were synthesized using the Claisen-Schmidt condensation technique. The synthesized compounds were then characterized using FT-IR, NMR, and MS. Further, synthesized the compounds were subjected to an in vitro cytotoxicity study using an MTT assay against the HCT-116 cell line. The therapeutic efficacy of novel chalcone derivative was evaluated against (Ehrlich Ascites Carcinoma) EAC and (Dalton's Lymphoma Ascites) DLA cell inoculated Swiss albino mice. The characterization of the compounds using FT-IR, NMR, and MS confirmed the formation of the new chalcone derivatives. One synthesized compound showed good cytotoxicity against the HCT-116 cell line with an IC50 value of 15.90 μg/ml. In the in vivo pharmacodynamic parameters, the S1 maintained stable body weight, decrease in tumour volume, and tumour weight, and increased the life span of cancer-induced mice. Haematological profiles such as RBC, WBC, Hb, and Platelet count revealed nearly normal levels in S1-treated mice in both EAC and DLA cell-inoculated mice. All the observations convey that the novel chalcone derivative (S1) has potency in dose-dependent anticancer activity comparable to 5-flurouracil.
Indexed as
Identifiers
40928655What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.